NATIONAL INCUBATOR SHIFTS INTO GEAR, ANNOUNCING VACCINE AND INFECTIOUS DISEASE INNOVATION COHORT Six Australian infectious disease innovations receive $10.48 million to accelerate commercialisation potential
With
Jenny Herz,
Co-Founder and Executive Director
Biointelect
Danielle Shand,
General Manager
Biointelect Venturer
SEGMENT
Filmed in Sydney | September 2026
Biointelect Venturer is Australia’s national incubator for infectious disease innovation, helping promising Australian scientific innovators accelerate their path from discovery to impact. Funded by the Australian Government’s Medical Research Future Fund (MRFF) through the 2024 BioMedTech Incubator grant opportunity, Biointelect Venturer combines catalytic non-dilutive funding with commercialisation expertise, strategic guidance, networks and tailored support to progress early-stage innovations towards commercial and investment readiness. Managed and operated by Biointelect, the incubator builds on Biointelect’s deep expertise and success in supporting early-stage biotech and medtech commercialisation.
Biointelect Venturer has announced six Australian infectious disease innovations will share $10.48 million in the incubator’s first funding round giving the successful research teams the ability to advance their early-stage breakthroughs to commercial and investment readiness.
– AdaptiVax Pty Ltd
– Ebivanta Therapeutics Pty Ltd
– ENA Respiratory Pty Ltd
– Proboxis Biotechnology Pty Ltd
– Saccharide Therapeutics Pty Ltd
– SAMMvax Pty Ltd
The recipients address significant local and global unmet health needs in infectious disease and include three vaccine offerings, a unique nasal antiviral technology and two vaccine platform technologies.
The projects will now enter the Biointelect Venturer incubation program for up to two years and receive non-dilutive funding, tailored commercialisation support, expert mentoring and access to national and international networks to help progress their technologies to secure commercial interest and funding.
Biointelect Venturer was established through a $32.9 million Medical Research Future Fund (MRFF) grant from the Australian Government’s MRFF Medical Research Commercialisation initiative. It will support two national cohort intakes, this being the first, and a dedicated top-up round for high-potential projects as part of the program.
Biointelect Venturer is helping to build local capability in translational research and commercialisation and supporting the creation and growth of Australian biotech companies developing health technologies across the infectious disease sector. Ultimately the ambition is to strengthen Australia’s position as a global infectious disease innovation hub.
Source: Adapted from Biointelect media release (August 2026)
-
Entering The New Health Frontier
A new parliamentary report ‘The New Frontier: Delivering better health for all Australians’ is recommending significant reforms to the health care system to ensure Australians have better and faster access to the wave of new medicines and technologies.
The bipartisan report makes 31 recommendations to reform Australia’s system for the regulation and reimbursement with the hope that patients will receive faster access to the latest medicines and technologies.
-
Landmark research projects tackle critical issues in emergency healthcare
For two decades, the demand for emergency department services in Australia has outpaced population growth and wait times have increased. In 2022-2023 more than 8.8 million emergency department presentations occurred nationwide.
While demand is a contributing factor, EDs are currently being impacted by various factors across the entire health system.
The Emergency Medicine Foundation (EMF) is a non-profit organisation funding innovative Australian research that improves the way people are cared for in a medical emergency. The aim of the research is to deliver better and more effective health services to save lives and money.
-
Caring for community
With a passion for helping people, Carina Fernandes in her final year at Western Sydney University received accolades as a nursing student. Now a recent graduate, having completed her Bachelor of Nursing (Advanced) degree, and recognised as an Emerging Nurse Leader 2021 by the Australian College of Nursing, Carina has her sights set on her new role in healthcare, at the same time keeping sustainability top of mind.
